Authors
Cyril E K Gavor-Kwashi, Oksana Ryabinina, Samuel Badu Nyarko, Naa Aku Addo, Joel Adu Twum, John Anyimadu, Vanessa Naa Torshie Mensah, Ebenezer Allotey Pappoe, Foster Kyei, Ansumana S Bockarie, Richard Kojo Yankah, Ebenezer Aniakwa-Bonsu, Richmond Owusu Ateko, Dee Blackhurst, Nicholas Ekow Thomford
Published in
PloS one. Volume 21. Issue 11. Pages e0362848. Epub Nov 17, 2026.
Abstract
Cardiometabolic multimorbidity (coexistence of hypertension, type 2 diabetes, metabolic syndrome and chronic kidney disease) is rising in sub‑Saharan Africa (SSA), but data integrating clinical, lifestyle and genetic determinants in Ghana are limited. This study aimed to characterise the burden of cardiometabolic multimorbidity among Ghanaian clinic attendees and evaluate the associations of clinical, lifestyle, and candidate genetic variants with hypertension, diabetes, metabolic syndrome, and CKD.
This cross-sectional study assessed 203 adults attending specialised clinics at a tertiary hospital in Cape Coast, Ghana, between 17 May 2023 and 30 April 2024. Data were collected on participants' sociodemographic and clinicodemographic characteristics, in addition to lifestyle information obtained through structured questionnaires. Selected candidate variants (TCF7L2 rs7903146, AGT rs699, ACE rs4343, LEPR rs1137101, ADRB3 rs4994, KCNJ11 rs5219, PPARG rs1801282, APOL1 risk variants) were genotyped. Multivariable logistic regression models were used to evaluate the determinants of blood pressure, elevated glucose levels, metabolic syndrome, and CKD. Receiver operating characteristic analysis compared the predictive performance of clinical/lifestyle, genetic, and combined models.
Over 80% of participants had ≥ 2 cardiometabolic conditions; > 80% were overweight/obese, and >2/3 met the metabolic syndrome criteria. Despite high treatment rates, uncontrolled BP and hyperglycaemia were common. Obesity was the strongest independent predictor of CKD (aORs:7-8 for Obese I/II). The use of glucose-lowering medication was associated with better glycaemic control (OR: 7.16, 95% CI: 3.31-15.47, p < 0.001), and antihypertensive treatment was correlated with lower odds of uncontrolled BP (aOR: 0.25, 95% CI: 0.07-0.90, p = 0.033). Among the genetic markers, the TCF7L2 rs7903146 CT genotype was associated with higher odds of hypertension (adjusted odds ratio [aOR]: 2.15, 95% CI: 1.06-4.37, p = 0.034). Most other variants, including APOL1, showed no consistent associations. Combined clinical, lifestyle, and genetic models had the highest discrimination (AUCs: 0.83-0.89), followed by clinical/lifestyle models (AUCs: 0.76-0.83), while genetic-only models performed poorly (AUCs: 0.63-0.67).
In this Ghanaian cohort, cardiometabolic multimorbidity is highly prevalent and appears to be driven predominantly by modifiable risk factors, particularly obesity. Immediate gains are likely from integrated risk factor management; however, genetic findings are exploratory and require replication in larger, community-based cohorts.
PMID:
43043938
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0